DNV Capital

Wuhan Binhui Biotechnology Co., Ltd., established in 2010 and headquartered in Wuhan, China, specializes in the development of virus injection preparations. Situated in the Optics Valley Bio City within the Donghu National Independent Innovation Demonstration Zone, the company focuses on creating innovative products and services in the oncology sector, encompassing both diagnosis and treatment. Binhui Biotech is dedicated to developing offerings with independent intellectual property rights, aiming to compete effectively on the international market.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.

Geneseeq Technology Inc., established in 2008 and based in Toronto, Canada, operates a clinical testing and diagnostic center specializing in next-generation sequencing (NGS) technologies. The company focuses on advancing precision medicine in cancer treatment by transforming patients' genomic information into actionable insights for healthcare providers. Geneseeq's laboratories have attained significant certifications, including those from China's National Center of Clinical Laboratories and the College of American Pathologists, ensuring high standards in clinical diagnostics. The company offers a range of personalized medical diagnostics and healthcare management services, including genetic screening and molecular diagnostics, aimed at enhancing the detection and treatment success of cancer.

Sonendo, Inc. is a medical technology company that focuses on advancing dental care through innovative devices for root canal therapy. Based in Laguna Hills, California, Sonendo has developed the GentleWave® System, which enhances the cleaning and disinfection of tooth canals, improving clinical outcomes and efficiency compared to traditional methods. The company operates primarily through two segments: the Product segment, which includes sales of the GentleWave System and its related instruments, and the Software segment, which encompasses TDO® Software—widely recognized as a leading practice management solution for endodontics. Since its incorporation in 2006, Sonendo has aimed to transform dentistry by promoting effective treatments that preserve tooth structure and enhance patient care.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

TruTag Technologies, Inc. is a leading authentication and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for product authentication across a broad range of industries including pharmaceuticals, food, consumer products, and industrial & electronic parts. TruTag’s authentication platform is complemented by its’ advanced hyperspectral imaging technology, which is focused on providing powerful next-generation inline quality assurance solutions and diagnostics. TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world.

Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.). Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries.